

Press release

Eukarÿs and PPRS Group announce their strategic and equity partnership

Paris, 23/11/2018

Founded in 2010, Eukarÿs has developed a new approach called synthetic gene therapy, which limits the safety risks entailed by viral gene therapy and offers effective, customised treatment of monogenic or multifactorial disorders. Philippe Jaïs, CSO and Founding CEO of Eukarÿs, explains, "PPRS Ventures' investment sanctions the validation of our technology and results obtained from animal testing. The strategic partnership with PPRS Group should enable Eukarÿs to speed up the development of our drug candidate portfolio".

In turn, Fabrice Arousseau, CEO of PPRS Group has declared "I am delighted with this new PPRS Ventures investment in one of the most promising companies in the field of gene therapy, which is opening up new horizons both in terms of technology and therapeutic indications, PPRS being specialised in pathologies of the central nervous system to date".

About Eukarÿs:

Supported by a high-level Scientific Board formed by Doctors Pierre Chambon, Philippe Kourilsky, Daniel Metzger, Steve Pascolo, Jean-Charles Duclos-Vallée, Dominique Franco and Christian Bréchet, Eukarÿs is a company of Evry Génopole, which has pioneered the C3P3 system and its flagship application: synthetic gene therapy. The C3P3 system, currently in its 3rd generation, is protected by granted patents and applications. Eukarÿs has won several competitions including I-Lab 2009 and 2011, ESSEC-SENAT 2013 and Techinnov 2014. Financed by family offices and non-dilutive funding since its creation, Eukarÿs welcomes PPRS Ventures and, on this occasion, its first institutional partner and shareholder.

The proprietary technology "C3P3" is the first ever artificial system developed by synthetic biology which enables high-performance production of messenger RNA and therefore proteins in eukaryotic living organisms or cells. By means of this potent proprietary expression system, Eukarÿs has developed a new non-viral approach, called synthetic gene therapy, designed to prevent any risk of integration into the host cell genome. Moreover, the synthetic gene therapy enables multi-gene assembly, which makes possible the treatment of both monogenic and multifactorial disorders.

Eukarÿs is building a pipeline of synthetic gene therapies to treat hepatic diseases, which currently consists of EUK-LPR (Eukarÿs Liver ProRegeneration) to prevent liver failure following major liver surgical resection and a drug candidate to treat a monogenic liver disease. Eukarÿs will soon extend its developments to immunotherapy and the treatment of disorders related to secretory protein deficiency.

Also based on its C3P3 expression technology, Eukarÿs develops tools for bioproduction of recombinant proteins and viruses to achieve increased production yields. These tools, currently non-GMP, are available for research applications under license agreements.

About PPRS Group:

Based in Paris, Colmar and near to Boston (Massachusetts), PPRS Group is an independent French company with a unique business model that specialises in the preclinical and clinical development of drugs and medical devices for the central nervous system. It is composed of an experienced multidisciplinary team of 35 employees who have participated in over 700 clinical trials and have developed more than 150 drug candidates. PPRS Group is currently working on 10 projects, 6 drugs and 4 medical devices. PPRS Ventures, the investment arm of the group, makes minority investments in medical projects aimed at personalised medicine.

Eukarÿs:
Philippe Jaïs
philippe.jais@eukarys.com
00 33 6 72 81 50 48

For media inquiries please contact:
Maxime Luthringer
communication@pprs-research.com
00 41 79 565 26 58

PPRS Ventures:
Baptiste Planat
bpl@pprs-research.com
00 33 6 07 38 41 23